Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Breyer, Johannes"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-15 z 15
    Tytuł:
    Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
    Autorzy:
    Breyer J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany. johannes.breyer@ukr.de.
    Eckstein M; Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Sikic D; Department of Urology and Pediatric Urology, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Wezel F; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Roghmann F; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Brehmer M; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.
    Wirtz RM; Stratifyer Molecular Pathology GmbH, Cologne, Germany.; Institute of Pathology, St. Elisabeth Hospital Köln-Hohenlind, Cologne, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Jarczyk J; Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Erben P; Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Bahlinger V; Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Goldschmidt F; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Fechner G; Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Chen J; Biostatistics, Cepheid Inc., Sunnyvale, CA, USA.
    Paxinos E; Medical and Scientific Affairs, Cepheid Inc., Sunnyvale, CA, USA.
    Bates M; Medical and Scientific Affairs, Cepheid Inc., Sunnyvale, CA, USA.
    Haas M; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Zengerling F; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Bolenz C; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Burger M; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Landshuter Str. 65, 93053, Regensburg, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Hartmann A; Institute of Pathology, Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Kriegmair MC; Department of Urology and Urosurgery, University Hospital Mannheim Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.; BRIDGE (Bladder Cancer Research Initiative for Drug Targets Germany) Consortium E.V., Mannheim, Germany.
    Pokaż więcej
    Corporate Authors:
    BRIDGE Consortium e.V.
    Źródło:
    Scientific reports [Sci Rep] 2023 Sep 18; Vol. 13 (1), pp. 15437. Date of Electronic Publication: 2023 Sep 18.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Urinary Bladder Neoplasms*/diagnosis
    Humans ; Urinary Bladder ; Cystoscopy ; Neoplasm, Residual ; Polymerase Chain Reaction
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava.
    Autorzy:
    Kotlyar MJ; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
    Krebs M; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
    Solimando AG; Guido Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.; IRCCS Istituto Tumori 'Giovanni Paolo II' of Bari, 70124 Bari, Italy.
    Marquardt A; Department of Pathology, Klinikum Stuttgart, 70174 Stuttgart, Germany.
    Burger M; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany.
    Kübler H; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
    Bargou R; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
    Kneitz S; Physiological Chemistry I, Theodor-Boveri-Institute, Biocenter, University of Würzburg, 97074 Würzburg, Germany.
    Otto W; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany.
    Breyer J; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany.
    Vergho DC; Department of Urology, Caritas St. Josef, University of Regensburg Medical Center, 93053 Regensburg, Germany.
    Kneitz B; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
    Kalogirou C; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Mar 26; Vol. 15 (7). Date of Electronic Publication: 2023 Mar 26.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer: Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors for Mortality.
    Autorzy:
    Engelmann SU; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Pickl C; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Haas M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Kaelble S; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Hartmann V; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Firsching M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Lehmann L; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Gužvić M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    van Rhijn BWG; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
    Breyer J; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Burger M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Mayr R; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Mar 15; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 15.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Body Composition as a Comorbidity-Independent Predictor of Survival following Nephroureterectomy for Urothelial Cancer of the Upper Urinary Tract.
    Autorzy:
    Pickl C; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Engelmann S; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Girtner F; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Gužvić M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    van Rhijn BWG; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
    Hartmann V; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Holbach S; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Kälble S; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Haas M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Rosenhammer B; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Breyer J; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Burger M; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Mayr R; Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstr. 65, 93053 Regensburg, Germany.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2023 Jan 10; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 10.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis.
    Autorzy:
    Riedel F; Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Münker M; Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany.
    Roghmann F; Department of Urology, Marien Hospital, Ruhr-University Bochum, 44625 Herne, Germany.
    Breyer J; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, 93053 Regensburg, Germany.
    Schnabel MJ; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, 93053 Regensburg, Germany.
    Burger M; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, 93053 Regensburg, Germany.
    Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Büttner T; Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany.
    Ritter M; Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany.
    Hiller K; National Center for Tumor Diseases (NCT) Heidelberg, 69120 Heidelberg, Germany.
    Wezel F; Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Bolenz C; Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Zengerling F; Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2022 Jun 09; Vol. 14 (12). Date of Electronic Publication: 2022 Jun 09.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer.
    Autorzy:
    Eckstein M; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Kimmel C; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Bruendl J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Weber F; Institute of Pathology, University of Regensburg, Regensburg, Germany.
    Denzinger S; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Gierth M; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Burger M; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Hartmann A; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Otto W; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
    Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2021 Sep 09; Vol. 11 (1), pp. 17981. Date of Electronic Publication: 2021 Sep 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Mucous Membrane/*pathology
    Urinary Bladder Neoplasms/*mortality
    Urinary Bladder Neoplasms/*pathology
    Aged ; Aged, 80 and over ; Cystectomy/methods ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Immunotherapy/methods ; Kaplan-Meier Estimate ; Male ; Mycobacterium bovis/immunology ; Neoplasm Invasiveness ; Neoplasm Staging ; Prognosis ; Progression-Free Survival ; Retrospective Studies ; Survival Rate ; Urinary Bladder Neoplasms/surgery
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Autorzy:
    Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Wirtz RM; STRATIFYER Molecular Pathology GmbH, 541713 Cologne, Germany.
    Breyer J; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
    Eckstein M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Weyerer V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Kubon J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Erben P; Department of Urology and Urosurgery, University Medical Centre Mannheim, 68167 Mannheim, Germany.; Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Bolenz C; Department of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Burger M; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
    Hartmann A; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Pokaż więcej
    Źródło:
    Life (Basel, Switzerland) [Life (Basel)] 2021 Jun 30; Vol. 11 (7). Date of Electronic Publication: 2021 Jun 30.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.
    Autorzy:
    Weyerer V; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
    Strissel PL; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Adjunct Affiliation With Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
    Strick R; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Sikic D; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Geppert CI; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Lange F; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
    Taubert H; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Wach S; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Breyer J; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology, University Hospital Regensburg, University of Regensburg, 93053 Regensburg, Germany.
    Bolenz C; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University of Ulm, 89081 Ulm, Germany.
    Erben P; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology, University Hospital Mannheim, Rupprecht-Karls-Universität Heidelberg, 68177 Mannheim, Germany.
    Schmitz-Draeger BJ; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Urologie 24, 90431 Nuremberg, Germany.
    Wullich B; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
    Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
    Pokaż więcej
    Źródło:
    Cancers [Cancers (Basel)] 2021 May 12; Vol. 13 (10). Date of Electronic Publication: 2021 May 12.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer.
    Autorzy:
    Hülsen S; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Lippolis E; Institute of Human Genetics, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Ferrazzi F; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.; Institute of Human Genetics, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.; Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Otto W; Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany.
    Distel L; Department of Radiation Therapy, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Fietkau R; Department of Radiation Therapy, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Denzinger S; Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany.
    Breyer J; Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany.
    Burger M; Caritas St. Josef Medical Center, Department of Urology, Regensburg University, 93053 Regensburg, Germany.
    Bertz S; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Eckstein M; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Ebner A; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Hartmann A; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Geppert CI; Institute of Pathology, Friedrich-Alexander-University, Erlangen-Nürnberg, 91054 Erlangen, Germany.
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2020 Nov 09; Vol. 21 (21). Date of Electronic Publication: 2020 Nov 09.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Lymphocytes, Tumor-Infiltrating/*immunology
    Urinary Bladder Neoplasms/*immunology
    Urinary Bladder Neoplasms/*pathology
    Adult ; Aged ; Aged, 80 and over ; Biomarkers/metabolism ; CD3 Complex/immunology ; CD8-Positive T-Lymphocytes/immunology ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging/methods ; Prognosis ; Tumor Microenvironment/immunology ; Urinary Bladder Neoplasms/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Autorzy:
    Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Wirtz RM; STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany.
    Jarczyk J; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Worst TS; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Porubsky S; Institute of Pathology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Kunath F; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Weyerer V; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Breyer J; Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
    Otto W; Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
    Rinaldetti S; Department of Hematology and Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Bolenz C; Department of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany.
    Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen, Germany.
    Erben P; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
    Pokaż więcej
    Źródło:
    Journal of clinical medicine [J Clin Med] 2020 Apr 02; Vol. 9 (4). Date of Electronic Publication: 2020 Apr 02.
    Typ publikacji:
    Journal Article
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Autorzy:
    Breyer J; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    Wirtz RM; STRATIFYER Molecular Pathology GmbH, Cologne, Germany.; Institute of Pathology, St Elisabeth Hospital Köln-Hohenlind, Cologne, Germany.
    Erben P; Department of Urology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
    Rinaldetti S; Department of Haematology and Oncology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
    Worst TS; Department of Urology, Medical Faculty Mannheim, University Medical Centre Mannheim, Heidelberg University, Mannheim, Germany.
    Stoehr R; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Eckstein M; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Sikic D; Department of Urology and Paediatric Urology, University Hospital Erlangen, Erlangen, Germany.
    Denzinger S; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    Burger M; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    Hartmann A; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Otto W; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2019 Jan; Vol. 123 (1), pp. 187-196. Date of Electronic Publication: 2018 Sep 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Forkhead Box Protein M1/*genetics
    Neoplasms, Multiple Primary/*genetics
    Urinary Bladder Neoplasms/*drug therapy
    Urinary Bladder Neoplasms/*genetics
    Administration, Intravesical ; Aged ; Antibiotics, Antineoplastic/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Keratin-20/genetics ; Ki-67 Antigen/genetics ; Male ; Middle Aged ; Mitomycin/therapeutic use ; Neoplasm Staging ; Prognosis ; Progression-Free Survival ; Proportional Hazards Models ; RNA, Messenger/metabolism ; Retrospective Studies ; Survival Rate ; Urinary Bladder Neoplasms/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.
    Autorzy:
    Eckstein M; Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany. .
    Wirtz RM; STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany. .; Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany. .
    Gross-Weege M; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. .
    Breyer J; Department of Urology, University of Regensburg, 93053 Regensburg, Germany. Johannes.breyer@ukr.de.
    Otto W; Department of Urology, University of Regensburg, 93053 Regensburg, Germany. .
    Stoehr R; Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany. .
    Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany. .
    Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, 91058 Erlangen, Germany. .
    Eidt S; Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany. .
    Burger M; Department of Urology, University of Regensburg, 93053 Regensburg, Germany. .
    Bolenz C; Department of Urology, University of Ulm, 89081 Ulm, Germany. .
    Nitschke K; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. .
    Porubsky S; Department of Pathology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. .
    Hartmann A; Institute of Pathology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany. .
    Erben P; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. .
    Pokaż więcej
    Źródło:
    International journal of molecular sciences [Int J Mol Sci] 2018 Oct 30; Vol. 19 (11). Date of Electronic Publication: 2018 Oct 30.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Gene Expression Regulation, Neoplastic*
    Urinary Bladder Neoplasms*/metabolism
    Urinary Bladder Neoplasms*/mortality
    Urinary Bladder Neoplasms*/pathology
    Keratin-5/*biosynthesis
    Neoplasm Proteins/*biosynthesis
    RNA, Messenger/*biosynthesis
    RNA, Neoplasm/*biosynthesis
    Urothelium/*metabolism
    Disease-Free Survival ; Female ; Humans ; Immunohistochemistry ; Keratin-20/biosynthesis ; Male ; Survival Rate ; Urothelium/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.
    Autorzy:
    Worst TS; Department of Urology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. .
    Weis CA; Institute of Pathology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
    Stöhr R; Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstraße 8-10, 91054, Erlangen, Germany.
    Bertz S; Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstraße 8-10, 91054, Erlangen, Germany.
    Eckstein M; Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstraße 8-10, 91054, Erlangen, Germany.
    Otto W; Department of Urology, University of Regensburg, Landshuter Straße 65, 93053, Regensburg, Germany.
    Breyer J; Department of Urology, University of Regensburg, Landshuter Straße 65, 93053, Regensburg, Germany.
    Hartmann A; Institute of Pathology, University of Erlangen-Nuremberg, Krankenhausstraße 8-10, 91054, Erlangen, Germany.
    Bolenz C; Department of Urology, University of Ulm, Prittwitzstraße 43, 89075, Ulm, Germany.
    Wirtz RM; STRATIFYER Molecular Pathology GmbH, Werthmannstraße 1, 50935, Cologne, Germany.; Institute of Pathology at the St Elisabeth Hospital Köln-Hohenlind, Werthmannstraße 1, 50935, Cologne, Germany.
    Erben P; Department of Urology, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2018 Sep 26; Vol. 8 (1), pp. 14383. Date of Electronic Publication: 2018 Sep 26.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gene Expression Regulation, Neoplastic*
    Cyclin-Dependent Kinase Inhibitor p16/*genetics
    Muscle Neoplasms/*secondary
    Neoplasm Invasiveness/*genetics
    Urinary Bladder Neoplasms/*genetics
    Urinary Bladder Neoplasms/*pathology
    Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Female ; Gene Expression Profiling ; Humans ; Male ; Middle Aged ; Muscle Neoplasms/diagnosis ; Muscle Neoplasms/genetics ; Muscle Neoplasms/pathology ; Neoplasm Invasiveness/diagnosis ; Neoplasm Invasiveness/pathology ; Prognosis ; RNA, Messenger/genetics ; Transcriptome ; Urinary Bladder Neoplasms/diagnosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.
    Autorzy:
    Otto W; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.; Member of the BRIDGE Consortium, Mannheim, Germany.
    van Rhijn BW; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
    Breyer J; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.; Member of the BRIDGE Consortium, Mannheim, Germany.
    Bertz S; Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany.
    Eckstein M; Member of the BRIDGE Consortium, Mannheim, Germany.; Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany.
    Mayr R; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.
    Lausenmeyer EM; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.
    Denzinger S; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.
    Burger M; Department of Urology, Caritas St. Josef Medical Center, Regensburg University, Regensburg, Germany.; Member of the BRIDGE Consortium, Mannheim, Germany.
    Hartmann A; Member of the BRIDGE Consortium, Mannheim, Germany.; Institute of Pathology, Nuremberg-Erlangen University, Erlangen, Germany.
    Pokaż więcej
    Źródło:
    International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2018 May; Vol. 25 (5), pp. 442-449. Date of Electronic Publication: 2018 Feb 22.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Neoplasm Staging*
    Carcinoma in Situ/*diagnosis
    Mucous Membrane/*pathology
    Urinary Bladder Neoplasms/*diagnosis
    Aged ; Carcinoma in Situ/mortality ; Carcinoma in Situ/surgery ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Neoplasm Invasiveness/pathology ; Predictive Value of Tests ; Proportional Hazards Models ; Time Factors ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/surgery ; Urologic Surgical Procedures ; World Health Organization
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cells.
    Autorzy:
    Weidemann A
    Breyer J
    Rehm M
    Eckardt KU
    Daniel C
    Cicha I
    Giehl K
    Goppelt-Struebe M; Department of Nephrology and Hypertension, Universitätsklinikum Erlangen, Universität Erlangen-Nürnberg, Loschgestrasse 8, 91054 Erlangen, Germany. .
    Pokaż więcej
    Źródło:
    Cell communication and signaling : CCS [Cell Commun Signal] 2013 Oct 21; Vol. 11, pp. 80. Date of Electronic Publication: 2013 Oct 21.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Actin Cytoskeleton/*metabolism
    Endothelial Cells/*drug effects
    Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
    Microvessels/*drug effects
    Prolyl-Hydroxylase Inhibitors/*pharmacology
    rac1 GTP-Binding Protein/*metabolism
    Actin Cytoskeleton/ultrastructure ; Actins/metabolism ; Amino Acids, Dicarboxylic/pharmacology ; Cell Movement ; Endothelial Cells/physiology ; Endothelial Cells/ultrastructure ; Human Umbilical Vein Endothelial Cells ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Microvessels/physiology ; Microvessels/ultrastructure ; Signal Transduction ; Spheroids, Cellular/cytology ; Spheroids, Cellular/physiology ; p21-Activated Kinases/metabolism ; rac1 GTP-Binding Protein/genetics ; rho-Associated Kinases/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-15 z 15

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies